Anti-IL2 Induction in Liver Transplantation with 93% Rejection-Free Patient and Graft Survival at 18 Months

Journal of Surgical Research

Volumn 138, Issue 2, 2007, Pages 198-204

  Ramirez, Carlo B ^a   Doria, Cataldo ^a   di Francesco, Fabrizio ^a   Iaria, Maurizio ^a   Kang, Yoogoo ^a   Marino, Ignazio R ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Anti IL2 receptor antibody; immunosuppression; liver transplant

Indexed keywords

ANTIBIOTIC AGENT; BASILIXIMAB; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON ALPHA2A; PREDNISONE; RIBAVIRIN; STEROID; TACROLIMUS; VIRUS RNA;

ACUTE GRAFT REJECTION; ADULT; AGED; ALLERGIC REACTION; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LIVER DISEASE; LIVER GRAFT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; ORGAN DONOR; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN INDUCTION; RATING SCALE; RECURRENT DISEASE; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT DURATION;

ACUTE DISEASE; ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIVER TRANSPLANTATION; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TACROLIMUS; TREATMENT OUTCOME;

EID: 33847678151     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2006.08.025     Document Type: Article

References (32)

1. Shapiro R., Young J.B., Milford E.L., et al. Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transpl 5 (2005) 874
2. Brennan D.C. Action, efficacy and toxicities: polyclonal anti-lymphocyte antibodies. In: Norman D.J., and Turka L.A. (Eds). Primer on Transplantation. (ed. 2) (2001), American Society of Transplantation, Mt. Laurel, NJ 152
3. Nashan B., Moore R., Amlot P., et al. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350 (1997) 1193
4. Amlot P.L., Rawlings E., Fernando O.N., et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 60 (1995) 748
5. Kahan B.D., Rajagopalan P.R., Hall M., and United States Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2- receptor monoclonal antibody. Transplantation 67 (1999) 276
6. Vincenti F., Kirkman R., Light S., et al., Daclizumab Triple Therapy Study Group. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338 (1998) 161
7. Ponticelli C., Yussim A., Cambi V., et al., Simulect Phase IV Study Group. A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 72 (2001) 1261
8. Lawen J.G., Davies E.A., Mourad G., et al., Simulect International Study Group. Randomized, double blind study of immuno-prophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil- containing triple therapy in renal transplantation. Transplantation 75 (2003) 37
9. Calmus Y., Scheele J.R., Gonzalez-Pinto I., et al. Immunoprophylaxis with basiliximab, a chimeric interleukin 2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 8 (2002) 123
10. Neuhaus P., Clavien P.A., Kittur D., et al., CHIC 304 International Liver Study Group. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double blind randomized placebo controlled trial. Liver Transpl 8 (2002) 132
11. Filipponi F., Callea F., Salizzoni M., et al. Double blind comparison of hepatitis C histological recurrence rate in HCV + liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 78 (2004) 1488
12. Marino I.R., Doria C., Scott V., et al. Efficacy and safety of basiliximab with a tacrolimus based regimen in liver transplant recipients. Transplantation 78 (2004) 886
13. Demetris A.J., Batts K.P., Dhillon A.P., et al. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 25 (1997) 658
14. Scheuer P.J. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13 (1991) 372
15. Brunt E.M. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 31 (2000) 241
16. Wiesner R.H., Demetris A.J., Belle S.H., et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 28 (1998) 638
17. McAlister V., Grant D., Roy A., et al. Post-transplant lympho-proliferative disorders in liver recipients treated with OKT3 or ALG induction immunosuppression. Transplant Proc 25 (1993) 1400
18. Gane E., Nauomov N., Qian K., et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 110 (1996) 167
19. Asfar S., Metrakos P., Fryer J., et al. Analysis of late deaths after liver transplantation. Transplantation 61 (1996) 1377
20. Kovarik J.M., Breidenbach T., Gerbeau C., et al. Disposition and immunodynamics of Basiliximab in liver allograft recipients. Clin Pharmacol Ther 64 (1998) 66
21. Kovarik J.M., Nashan B., Neuhaus P., et al. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clin Pharmacol Ther 69 (2001) 201
22. Jain A., Kashyap R., Dodson F., et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation 72 (2001) 1091
23. Singh N., Gayowski T., Wannstedt C.F., et al. Interferon alpha therapy for hepatitis C virus recurrence after liver transplantation: long term response with maintenance therapy. Clin Transplant 10 (1996) 348
24. Gayowski T., Singh N., Marino I.R., et al. Hepatitis C genotypes in liver transplant recipients: impact on post-transplant recurrence, infections, response to interferon-α therapy and outcome. Transplantation 64 (1997) 422
25. Schluger L.K., Sheiner P.A., Thung S.N., et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 23 (1996) 971
26. Dickson R.C., Caldwell S.H., Ishitani M.B., et al. Clinical and histological patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation 61 (1996) 701
27. Eason J.D., Nair S., Cohen A.J., et al. Steroid free liver transplantation using rabbit anti-thymocyte globulin and early tacrolimus monotherapy. Transplantation 75 (2003) 1396
28. Belli L., Alberti A., Vangeli M., et al. Tapering off steroids 3 months after liver transplantation is not detrimental for hepatitis C virus disease recurrence. Liver Transpl 9 (2003) 201
29. Brillianti S., Vivarelli M., De Ruvo N., et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 8 (2002) 884
30. Kato T., Neff G., Montalbano M., et al. Steroid-free induction with tacrolimus and daclizumab in liver transplant recipients with hepatitis C: a preliminary report of a prospective randomized trial. Am J Transpl 1 suppl 1 (2001) 179
31. Kusne S., Dummer J.S., Singh N., et al. Infections after liver transplantation: an analysis of 101 cases. Medicine (Baltimore) 67 (1988) 132
32. Paya C.V., Hermans P.E., Washington II J.A., et al. Incidence, distribution and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc 64 (1989) 555